

19 August 2026

BioCina appointed to GMP manufacture TRP-8803 (IV psilocin)

- **Strategic agreement signed with TGA-licensed, FDA- and EMA-aligned CDMO BioCina to manufacture TRP-8803**
- **Agreement establishes key foundation for the broader international development and commercialisation of TRP-8803**
- **BioCina has an established global pharmaceutical manufacturing capability supplying over 100 countries from facilities in Perth and Adelaide**
- **BioCina will produce GMP clinical drug supply and generate key pharmaceutical and stability data required for the US and other major international markets**
- **TRP-8803 positioned for rapid progression into international phase 2/3 trials and global deployment of precision IV-psilocin therapy**
- **Agreement supports expanding clinical program, including recently approved 72-patient trial evaluating TRP-8803 across eight indications with high-unmet clinical need**
- **Entropy retains full ownership of all TRP-8803 IP and product-specific know-how under the Agreement**

Melbourne, Australia – Entropy Neurodynamics Limited (**‘Entropy Neurodynamics’** or the **‘Company’**) (**ASX: ENP**), a clinical-stage biotechnology company developing precision-controlled psychedelic therapies, advises that it has executed a Development and Manufacturing Services Agreement (“Agreement”) with BioCina, a leading Contract Development and Manufacturing Organisation (“CDMO”) to GMP manufacture the Company’s proprietary TRP-8803 (IV-infused psilocin) formulation.

BioCina is an end-to-end CDMO spanning drug substance and drug product manufacturing from clinical development through commercial supply. The company specialises in aseptic fill-finish across Blow-Fill-Seal, vials, pre-filled syringes and cartridges, and cytotoxic sterile injectables (unrelated to TRP-8803), as well as biologics manufacturing across microbial, pDNA, mRNA and LNP modalities. BioCina holds an active TGA license for Schedule 8 controlled substances and maintains the regulatory framework required to handle Schedule 9 APIs, including psilocin. As a TGA-licensed cGMP manufacturer with a track record of FDA inspections and EMA-aligned quality systems, BioCina manufactures more than 225 million sterile units annually and supplies products to more than 140 countries worldwide.

The Agreement represents an important strategic milestone in the ongoing development of TRP-8803, establishing the pharmaceutical manufacturing capabilities required to support the program as it progresses beyond current clinical development activities and towards broader international clinical, regulatory and commercial opportunities.

TRP-8803 is Entropy’s proprietary IV-infused psilocin formulation. It is designed to



overcome the variability and unpredictability of oral psilocybin, enabling consistent therapeutic exposure, provides precise control over the onset, intensity and duration of the psychedelic experience and a reproducible treatment profile suitable for large-scale clinical deployment.

The Company is currently advancing TRP-8803 through an expanding clinical program, which includes its recently approved 72-patient study across eight neuropsychiatric indications of high-unmet clinical need (refer ASX announcement: 4 August 2026).

Establishing a robust and scalable manufacturing process is a critical component of the Company's Phase 2/3 trial and commercialisation strategy. The Agreement with BioCina provides the manufacturing capability to support international clinical trials and future regulatory requirements, and subject to successful clinical development and regulatory approval, commercial-scale supply.

Under the Agreement, BioCina will undertake a comprehensive program encompassing analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches. The pharmaceutical and stability data generated under this program will form a core component of Entropy's regulatory submissions in the United States, Europe and other major markets, enabling into late-stage clinical development of TRP-8803.

TRP-8803 will be GMP manufactured at BioCina's Perth facility using its Cytiva SA25 robotic aseptic filling line with TRP-8803 filled into sterile 10 mL glass vials. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.

Importantly, the work being undertaken with BioCina will establish a consistent and scalable pharmaceutical manufacturing capacity that can be leveraged across Entropy's full TRP-8803 development rather than being limited to any single clinical study or indication. Under the Agreement Entropy retains full ownership of all TRP-8803 IP and product-specific know-how.

Management commentary:

BioCina CEO, Dr Thomas Broudy said: *"We are pleased to partner with Entropy Neurodynamics on the TRP-8803 program. BioCina has significant experience supporting innovative pharmaceutical products through clinical development and commercialisation, backed by established sterile manufacturing infrastructure and global supply capabilities. We look forward to working with Entropy to establish a scalable manufacturing process capable of supporting the continued development of TRP-8803."*

CEO, Mr Jason Carroll said: *"Our agreement with BioCina is an important strategic step in building the infrastructure required to realise the broader potential of TRP-8803."*

We are generating an expanding body of clinical evidence around our precision-controlled IV approach to psychedelic therapy and, as that program develops, it is important that we build the pharmaceutical manufacturing capability alongside it.

As our multi-indication development strategy advances, this agreement with BioCina



ensures that as our clinical evidence base expands, TRP-8803 is supported by a manufacturing engine capable of rapid scale-up, global distribution and commercial-grade consistency.

With scalable GMP manufacturing now secured, Entropy is positioned to advance TRP-8803 as a globally relevant therapeutic platform across multiple indications, multiple geographies and with multiple regulatory pathways."

This announcement has been authorised by the Board of Entropy Neurodynamics Limited.

– ENDS –

INVESTOR & MEDIA CONTACT

Jason Carroll

Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@trypterapeutics.com

Henry Jordan

Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Entropy Neurodynamics Limited

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials demonstrated the clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done via the following steps:

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password*
- *If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.*
- *Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'.*

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can

include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.